Prednisolone reduces the ability of serum to activate the IGF1 receptor in vitro without affecting circulating total or free IGF1

European Journal of Endocrinology

Volumn 168, Issue 1, 2013, Pages 1-8

  Frystyk, Jan ^a,b   Schou, Anders J ^c   Heuck, Carsten ^b,c   Vorum, Henrik ^d   Lyngholm, Mikkel ^b   Flyvbjerg, Allan ^a,b   Wolthers, Ole D ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Dytmarsken   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PLACEBO; PREDNISOLONE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SULFATE; THYMIDINE;

ADOLESCENT; ARTICLE; ASTHMA; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ASTHMA; CHILD; CROSS-OVER STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR I; MALE; PLACEBOS; PREDNISOLONE; RECEPTOR, IGF TYPE 1;

EID: 84871962502     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0518     Document Type: Article

References (43)

1. Schakman O, Gilson H, Kalista S & Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Hormone Research 2009 72 (Suppl 1) 36-41. (doi:10.1159/000229762)
2. Olney RC. Mechanisms of impaired growth: effect of steroids on bone and cartilage. Hormone Research 2009 72 (Suppl 1) 30-35. (doi:10.1159/000229761)
3. Mauras N. Can growth hormone counteract the catabolic effects of steroids? Hormone Research 2009 72 (Suppl 1) 48-54. (doi:10.1159/000229764)
4. Mehls O, Himmele R, Homme M, Kiepe D & Klaus G. The interaction of glucocorticoids with the growth hormone-insulinlike growth factor axis and its effects on growth plate chondrocytes and bone cells. Journal of Pediatric Endocrinology & Metabolism 2001 14 (Suppl 6) 1475-1482. (Pubitemid 33730761)
5. van der Eerden BC, Karperien M & Wit JM. Systemic and local regulation of the growth plate. Endocrine Reviews 2003 24 782-801. (doi:10.1210/er.2002-0033)
6. Unterman TG & Phillips LS. Glucocorticoid effects on somatomedins and somatomedin inhibitors. Journal of Clinical Endocrinology and Metabolism 1985 61 618-626. (doi:10.1210/jcem-61-4-618)
7. Miell JP, Taylor AM, Jones J, Holly JM, Gaillard RC, Pralong FP, Ross RJ & Blum WF. The effects of dexamethasone treatment on immunoreactive and bioactive insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers. Journal of Endocrinology 1993 136 525-533. (doi:10.1677/joe.0. 1360525)
8. Elders MJ, Wingfield BS, McNatt ML, Clarke JS & Hughes ER. Glucocorticoid therapy in children. Effect on somatomedin secretion. American Journal of Diseases of Children 1975 129 1393-1396.
9. Skjærbæk C, Frystyk J, Grøfte T, Flyvbjerg A, Lewitt MS, Baxter RC & Ørskov H. Serum free insulin-like growth factor-I is dosedependently decreased by methylprednisolone and related to body weight changes in rats. Growth Hormone & IGF Research 1999 9 74-80. (doi:10.1054/ghir.1999.0090)
10. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Hormone & IGF Research 2003 13 113-170. (doi:10.1016/S1096-6374(03)00038-8)
11. Van Doorn J, Cornelissen AJ & Buul-Offers SC. Plasma levels of insulin-like growth factor binding protein-4 (IGFBP-4) under normal and pathological conditions. Clinical Endocrinology 2001 54 655-664. (doi:10.1046/j.1365-2265.2001.01248.x)
12. Eivindson M, Grønbæk H, Flyvbjerg A, Frystyk J, Zimmermann-Nielsen E & Dahlerup JF. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment. Growth Hormone & IGF Research 2007 17 33-40. (doi:10.1016/j.ghir.2006.10.003)
13. Hickson RC, Oehler DT, Byerly RJ & Unterman TG. Protective effect of glutamine from glucocorticoid-induced muscle atrophy occurs without alterations in circulating insulin-like growth factor (IGF)-I and IGF-binding protein levels. Proceedings of the Society for Experimental Biology and Medicine 1997 216 65-71.
14. Sadick MD, Intintoli A, Quarmby V, McCoy A, Canova-Davis E & Ling V. Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays. Journal of Pharmaceutical and Biomedical Analysis 1999 19 883-891. (doi:10.1016/S0731-7085(98)00144-7)
15. Schou AJ, Heuck C &Wolthers OD. Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound. Steroids 2003 68 525-531. (doi:10.1016/S0039- 128X(03)00086-2)
16. Schou AJ, Heuck C & Wolthers OD. Ultrasound of skin in prednisolone-induced short-term growth suppression. Journal of Pediatric Endocrinology & Metabolism 2003 16 973-980. (Pubitemid 37259184)
17. Chen JW, Ledet T, Ørskov H, Jessen N, Lund S, Whittaker J, De Meyts P, Larsen MB, Christiansen JS & Frystyk J. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. American Journal of Physiology. Endocrinology and Metabolism 2003 284 E1149-E1155. (Pubitemid 36617461)
18. Frystyk J. Quantification of the GH/IGF-axis components: lessons from human studies. Domestic Animal Endocrinology 2012 43 186-197. (doi:10.1016/j.domaniend.2011.11.005)
19. Frystyk J, Dinesen B & Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulinlike growth factor I and II. Growth Regulation 1995 5 169-176. (Pubitemid 26018330)
20. Ivarsen P, Chen JW, Tietze I, Christiansen JS, Flyvbjerg A & Frystyk J. Marked reductions in bioactive insulin-like growth factor I (IGF-I) during hemodialysis. Growth Hormone & IGF Research 2010 20 156-161. (doi:10.1016/j.ghir.2009.12.001)
21. Frystyk J, Højlund K, Rasmussen KN, Jørgensen SP, Wildner-ChristensenM & Ørskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of insulin-like growth factor-I (IGF-I) and IGF-binding protein-1 in human serum. Journal of Clinical Endocrinology and Metabolism 2002 87 260-266. (doi:10.1210/jc.87.1.260)
22. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW & Flyvbjerg A. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. Journal of Clinical Endocrinology and Metabolism 2003 88 132-135. (doi:10.1210/jc.2002-021349)
23. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S & Binoux M. Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. Analytical Biochemistry 1986 154 138-143. (doi:10.1016/0003-2697(86)90507-5)
24. Jeyaratnaganthan N, Grønbæk H, Holland-Fischer P, Espelund U, Chen JW, Flyvbjerg A, Vilstrup H & Frystyk J. Ascites from patients with alcoholic liver cirrhosis contains higher IGF-I bioactivity than serum. Clinical Endocrinology 2010 72 625-632. (doi:10.1111/j.1365-2265.2009.03707.x)
25. Mandal N, Heegaard S, Prause JU, Honore B & Vorum H. Ocular proteomics with emphasis on two-dimensional gel electrophoresis and mass spectrometry. Biological Procedures Online 2009 12 56-88. (doi:10.1007/s12575- 009-9019-7)
26. Østergaard L, Honore B, Thorsen LB, Baandrup J, Eskildsen-Helmond Y, Laursen BE, Vorum H, Mulvany MJ & Simonsen U. Pulmonary pressure reduction attenuates expression of proteins identified by lung proteomic profiling in pulmonary hypertensive rats. Proteomics 2011 11 4492-4502. (doi:10.1002/pmic.201100171)
27. Mortz E, Krogh TN, Vorum H & Gorg A. Improved silver staining protocols for high sensitivity protein identification using matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics 2001 1 1359-1363. (doi:10.1002/1615-9861(200111)1:11!1359::AID-PROT1359O3.0.CO;2-Q)
28. Argente J, Caballo N, Barrios V, Munoz MT, Pozo J, Chowen JA, Morande G & Hernandez M. Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short- and long-term weight recuperation. Journal of Clinical Endocrinology and Metabolism 1997 82 2084-2092. (doi:10.1210/jc.82.7.2084)
29. Støving RK, Chen JW, Glintborg D, Brixen K, Flyvbjerg A, Horder K & Frystyk J. Bioactive insulin-like growth factor (IGF) I and IGF-binding protein-1 in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2007 92 2323-2329. (doi:10.1210/jc.2006-1926)
30. Frystyk J, Ivarsen P, Skjærbæk C, Flyvbjerg A, Pedersen EB & Ørskov H. Serum free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney International 1999 56 2076-2084. (doi:10.1046/j.1523-1755.1999.00798.x)
31. Bereket A, Lang CH, Blethen SL, Ng LC & Wilson TA. Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children. Clinical Endocrinology 1996 45 321-326. (doi:10.1046/j.1365-2265.1996. 7760786.x)
32. Dall R, Wolthers T, Flyvbjerg A, Grøfte T, Christiansen JS & Jørgensen JO. No influence of prednisolone on IGFBP-3 proteolysis in healthy young men. Hormone Research 2001 55 95-101. (doi:10.1159/000049977)
33. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ & Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. Journal of Clinical Endocrinology and Metabolism 1995 80 2700-2708. (doi:10.1210/jc.80. 9.2700)
34. Lalou C, Lassarre C & Binoux M. A proteolytic fragment of insulinlike growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 1996 137 3206-3212. (doi:10.1210/en.137.8.3206)
35. Zhou R, Diehl D, Hoeflich A, Lahm H & Wolf E. IGF-binding protein-4: biochemical characteristics and functional consequences. Journal of Endocrinology 2003 178 177-193. (doi:10.1677/joe.0.1780177)
36. Cox D, Brennan M & Moran N. Integrins as therapeutic targets: lessons and opportunities. Nature Reviews. Drug Discovery 2010 9 804-820. (doi:10.1038/nrd3266)
37. Clemmons DR & Maile LA. Minireview: integral membrane proteins that function coordinately with the insulin-like growth factor I receptor to regulate intracellular signaling. Endocrinology 2003 144 1664-1670. (doi:10.1210/en. 2002-221102)
38. Matozaki T, Murata Y, Saito Y, Okazawa H & Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Science 2009 100 1786-1793. (doi:10.1111/j.1349-7006.2009. 01257.x)
39. Kuemmerle JF. Occupation of a-V-b-3-integrin by endogenous ligands modulates IGF-I receptor activation and proliferation of human intestinal smooth muscle. American Journal of Physiology. Gastrointestinal and Liver Physiology 2006 290 G1194-G1202. (doi:10.1152/ajpgi.00345.2005)
40. Carver KC, Piazza TM & Schuler LA. Prolactin enhances insulinlike growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. Journal of Biological Chemistry 2010 285 8003-8012. (doi:10.1074/jbc.M109.066480)
41. Wolthers OD. Methodological aspects of short-term knemometry in the assessment of exogenous glucocorticoid-induced growth suppression in children. Annals of Human Biology 1997 24 539-546. (doi:10.1080/03014469700005302)
42. Fernandez-Cancio M, Esteban C, Carrascosa A, Toran N, Andaluz P & Audi L. IGF-I and not IGF-II expression is regulated by glucocorticoids in human fetal epiphyseal chondrocytes. Growth Hormone & IGF Research 2008 18 497-505. (doi:10.1016/j.ghir.2008.04.004)
43. Macrae VE, Ahmed SF, Mushtaq T & Farquharson C. IGF-I signalling in bone growth: inhibitory actions of dexamethasone and IL-1b. Growth Hormone & IGF Research 2007 17 435-439. (doi:10.1016/j.ghir.2007.05.002)